Wave Life Sciences Inc(WVE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.07 | Insider Own | 16.18% | Shs Outstand | 197.2M | Perf Week | 8.01% |
| Market Cap | 0.72B | Forward P/E | - | EPS next Y | -18.89% | Insider Trans | -0.08% | Shs Float | 165.3M | Perf Month | - |
| Enterprise Value | 0.33B | PEG | - | EPS next Q | -0.32 | Inst Own | 83.98% | Short Float | 12.8% | Perf Quarter | -36.81% |
| Income | -0.21B | P/S | 10.12 | EPS this Y | 8.96% | Inst Trans | 6.7% | Short Ratio | 6.51 | Perf Half Y | -48.37% |
| Sales | 0.07B | P/B | 1.79 | EPS next 5Y | -1.58% | ROA | -56.19% | Short Interest | 21.17M | Perf YTD | -78.59% |
| Book/sh | 2.04 | P/C | 1.67 | EPS past 3/5Y | 16.1% 20.52% | ROE | -78.8% | 52W High | -83.25% ($21.73) | Perf Year | -52.04% |
| Cash/sh | 2.18 | P/FCF | - | Sales past 3/5Y | 127.08% 16.31% | ROIC | -47.76% | 52W Low | 19.74% ($3.04) | Perf 3Y | -31.58% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -45.17% | Gross Margin | 86.99% | Volatility(W/M) | 7.01% 5.91% | Perf 5Y | -18.75% |
| Dividend TTM | - | EV/Sales | 4.66 | Sales Y/Y TTM | -35.07% | Oper. Margin | -320.94% | ATR (14) | 0.22 | Perf 10Y | -88.39% |
| Dividend Ex-Date | - | Quick Ratio | 8.38 | EPS Q/Q | 5.55% | Profit Margin | -296.86% | RSI (14) | 50.86 | Recom | 1.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.38 | Sales Q/Q | 72.95% | SMA20 | 7.03% ($3.4) | Beta | -1.42 | Target Price | $18.59 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/10/27 | SMA50 | -11.95% ($4.13) | Rel Volume | 1.31 | Prev Close | $3.45 |
| Employees | 317 | LT Debt/Eq | 0.1 | EPS/Sales Surpr. | 8.81% 191.6% | SMA200 | -51.67% ($7.53) | Avg Volume(3M) | 3.25M | Price | $3.64 |
| IPO | 2015/11/11 | Option/Short | Yes/Yes | Trades | 12218 | Volume | 4,263,473 | Change | 5.51% |
🧬 Wave Life Sciences is a biotech company developing next-generation genetic medicines that target RNA, built on its proprietary PRISM platform. By combining multiple modalities—including RNA editing, splicing, interference, and antisense silencing—the company aims to address genetically defined diseases such as alpha-1 antitrypsin deficiency, obesity, and liver disease.
Over the past 1 year, on the lower side
83% below its 1-year high.
Traded more than usual. That is 131% of its average volume.
WVE has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +9.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,012. Peers typically go for $1,237.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -18.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 84.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #186 of 594 in the industry
Based on market cap of $718M.
ATTO#185 Attovia Therapeutics Inc $721M PER - WVE#186 Wave Life Sciences Inc $718M PER - 
FDMT#187 4D Molecular Therapeutics Inc $714M PER - 
ACHV#188 Achieve Life Sciences Inc $705M PER - 
IAM#189 Iambic Therapeutics Inc $701M PER - 
FAQ
What kind of company is WVE?
WVE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of WVE?
The market cap of WVE is approximately $718M, ranking 2,862 within its sector.
What is the 52-week high and low for WVE?
WVE has recorded a 52-week high of $21.73 and a low of $3.04.
